98%
921
2 minutes
20
Purpose: Bladder cancer is one of the ten most common cancers in the world, with a high incidence rate and mortality, and therefore a major burden on the global health care system. PID1 (Phosphotyrosine Interaction Domain 1) functions as an intracellular receptor protein for LRP1. The purpose of this study was to explore the role of PID1 in bladder cancer.
Methods: RNA-seq data analysis was conducted on 404 BLCA specimens and 28 normal specimens to identify differentially expressed genes. The findings indicated a strong correlation between PID1 expression levels and bladder cancer. We constructed a bladder cancer cell line stably overexpressing PID1 and assessed its impact on cell proliferation and migration. Additionally, We used RT-112 cells to induce tumor formation in nude mice to study the function of the gene in vivo.
Results: PID1 expression was notably low in bladder cancer tissues. Compared to SV-HUC-1, RT-112, and SCaBER bladder cells exhibited significantly reduced PID1 expression. Overexpressing PID1 in cells led to the promotion of apoptosis in bladder cancer cells and suppressed cell proliferation and metastasis. In vivo, the overexpression of PID1 demonstrated a significant inhibitory effect on bladder cancer. Furthermore, it was capable of activating the AMPK-mTOR signaling pathway, thereby inhibiting tumor progression.
Conclusion: PID1 exhibits a potent inhibitory effect on bladder cancer and activates the AMPK-mTOR signaling pathway to hinder tumor growth.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302987 | PMC |
http://dx.doi.org/10.2147/RRU.S530209 | DOI Listing |
J Med Chem
September 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery o
Aberrant activation of fibroblast growth factor receptors (FGFRs) plays a critical role in tumorigenesis across multiple cancer types, driving the development of various FGFR inhibitors. Despite clinical advances, therapeutic efficacy remains limited by the emergence of drug resistance, primarily mediated by gatekeeper mutations in FGFRs. To overcome this challenge, we designed and synthesized a novel series of 7-(1-methyl-1-indole-3-yl)-5-pyrrolo[2,3-]pyrazine derivatives as covalent pan-FGFR inhibitors targeting both wild-type and gatekeeper mutants.
View Article and Find Full Text PDFMol Carcinog
September 2025
Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
B cells located in tertiary lymphoid structures (TLSs) may undergo clonal expansion, somatic hypermutation, isotype switching, and tumor-specific antibody production, suggesting that antibody-producing plasma cells may be involved in antitumor immunity. This study used a combination of single-cell sequencing (five samples from our center, and four samples from PRJNA662018) and spatial transcriptome (one sample from our center, and four samples from GSE169379) research methods to investigate the relationship between TLSs and the immunoglobulin repertoire in muscle invasive bladder cancer (MIBC). 405 patients with MIBC from TCGA and 348 patients with metastatic urothelial carcinoma on PD-L1 inhibitor treatment from the IMvigor210 trial were included in this study.
View Article and Find Full Text PDFUrol Case Rep
September 2025
Main Line Health, Division of Urology, Wynnewood, PA, USA.
Muscle-invasive bladder cancer (MIBC) with cardiac metastasis typically carries a very poor prognosis. A Black woman in her 70s developed high-grade urothelial carcinoma with squamous differentiation invading the bladder muscle. Despite chemotherapy, radiation, and nephrostomy, the disease progressed.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
In metastatic colorectal cancer (mCRC) patients with proficient mismatch repair (pMMR)/microsatellite stability (MSS), beyond third-line therapies were extremely limited. Here, we reported a case of a 21-year-old male patient with pMMR/MSS mCRC who failed to respond to both first- and second-line treatment and subsequently received non-standard third-line therapy at a local hospital. This patient was referred to our hospital, and we initiated salvage therapies.
View Article and Find Full Text PDF